返回 Agendas
Session 3B: Non Clinical Track: mRNA Therapeutics
Session Chair(s)
Jennifer Marlowe, PHD
Senior Director, Preclinical Development
bluebirdbio, United States
Sree Rayavarapu, DVM, PHD
Toxicologist
FDA, United States
A new therapeutic modality, mRNA therapeutics, is the topic for this session. Representatives from three different companies will present nonclinical data associated with their new mRNA therapeutic candidates including a self-replicating mRNA vaccine.
Speaker(s)
Translation of Messenger RNA Therapeutics from Pre-clinical Research into Clinical Studies
Pad Chivukula, PHD
Arcturus Therapeutics, United States
CSO & COO
Lipid Nanoparticle-based mRNA Therapeutics
Ying Tam, PHD, MSC
Acuitas Therapeutics, Canada
Director of Preclinical Studies
Self-amplifing mRNA Vaccines
Andrew J. Geall
Avidity Nanomedicines, United States
Vice President, Formulations and Chemistry
Panel Discussion
All Session Speakers, United States